MXPA03008359A - Composiciones farmaceuticas a base de timosina (beta)4 (t(beta)4), analogos, isorformas y otros derivados para el tratamiento de desordenes del ojo y tejido circundante, y metodos para esto. - Google Patents

Composiciones farmaceuticas a base de timosina (beta)4 (t(beta)4), analogos, isorformas y otros derivados para el tratamiento de desordenes del ojo y tejido circundante, y metodos para esto.

Info

Publication number
MXPA03008359A
MXPA03008359A MXPA03008359A MXPA03008359A MXPA03008359A MX PA03008359 A MXPA03008359 A MX PA03008359A MX PA03008359 A MXPA03008359 A MX PA03008359A MX PA03008359 A MXPA03008359 A MX PA03008359A MX PA03008359 A MXPA03008359 A MX PA03008359A
Authority
MX
Mexico
Prior art keywords
eye
degeneration
composition
polypeptide
thymosin
Prior art date
Application number
MXPA03008359A
Other languages
English (en)
Spanish (es)
Inventor
L Goldstein Allan
Original Assignee
Regenerx Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals filed Critical Regenerx Biopharmaceuticals
Publication of MXPA03008359A publication Critical patent/MXPA03008359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MXPA03008359A 2001-03-15 2002-03-14 Composiciones farmaceuticas a base de timosina (beta)4 (t(beta)4), analogos, isorformas y otros derivados para el tratamiento de desordenes del ojo y tejido circundante, y metodos para esto. MXPA03008359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27564501P 2001-03-15 2001-03-15
PCT/US2002/007730 WO2002074193A2 (en) 2001-03-15 2002-03-14 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

Publications (1)

Publication Number Publication Date
MXPA03008359A true MXPA03008359A (es) 2004-10-15

Family

ID=23053251

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008359A MXPA03008359A (es) 2001-03-15 2002-03-14 Composiciones farmaceuticas a base de timosina (beta)4 (t(beta)4), analogos, isorformas y otros derivados para el tratamiento de desordenes del ojo y tejido circundante, y metodos para esto.

Country Status (8)

Country Link
US (1) US20040131626A1 (enExample)
EP (1) EP1383529A4 (enExample)
JP (2) JP2005506293A (enExample)
CN (2) CN101195025A (enExample)
AU (2) AU2002255736B2 (enExample)
CA (1) CA2441147A1 (enExample)
MX (1) MXPA03008359A (enExample)
WO (1) WO2002074193A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531318B2 (en) * 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
WO2006076255A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing microbial eye infection
CA2612522A1 (en) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods
CN100372572C (zh) * 2005-09-29 2008-03-05 北京诺思兰德生物技术有限责任公司 携带人胸腺素β4基因的重组质粒
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
US9867871B2 (en) 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
CN102924573B (zh) * 2012-11-13 2014-07-23 兆科药业（广州）有限公司 一种肌动蛋白结合肽及其用途
AU2015336396B2 (en) * 2014-10-22 2020-12-10 HLB Therapeutics Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
KR20170021667A (ko) * 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
CN106692949B (zh) * 2016-12-23 2022-03-15 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
AU2018372396A1 (en) * 2017-11-24 2020-06-25 HLB Therapeutics Co., Ltd. Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
CN113599371A (zh) * 2021-09-06 2021-11-05 郑州大学 二甲双胍在制备预防胸腺退化和/或促进胸腺组织再生药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4543340A (en) * 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
AT401180B (de) * 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
JP3128203B2 (ja) * 1997-02-10 2001-01-29 一男 坪田 分泌腺細胞とリンパ球との接着阻害剤
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
PT1100529E (pt) * 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions

Also Published As

Publication number Publication date
CA2441147A1 (en) 2002-09-26
CN101195025A (zh) 2008-06-11
WO2002074193A2 (en) 2002-09-26
AU2002255736B2 (en) 2006-08-31
CN100360174C (zh) 2008-01-09
JP2005506293A (ja) 2005-03-03
US20040131626A1 (en) 2004-07-08
EP1383529A2 (en) 2004-01-28
WO2002074193A3 (en) 2003-12-04
AU2008261127A1 (en) 2009-01-15
CN1638789A (zh) 2005-07-13
EP1383529A4 (en) 2005-06-29
HK1074577A1 (en) 2005-11-18
JP2009179638A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
AU2008261127A1 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta 4 (TBeta4), Analogues, Isoforms and Other Derivatives
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
US20080182780A1 (en) Method of Preventing or Reducing Scarring of Human Skin
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
US20080096817A1 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2006204785B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
AU2002309842B2 (en) Treating epidermlyosis bullosa with thymosin beta 4
AU2006233251B2 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
AU2004308378A1 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
JP2007521336A5 (enExample)
AU2002309842A1 (en) Treating epidermlyosis bullosa with thymosin beta 4
HK1074577B (en) THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
HK1118017A (en) THE USE OF THYMOSIN β4, ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
US20040170625A1 (en) Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
WO2020128616A2 (en) Methods and compositions for controlling cell migration and proliferation
HK40023769A (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
MXPA06006849A (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent

Legal Events

Date Code Title Description
FA Abandonment or withdrawal